{
    "clinical_study": {
        "@rank": "84107", 
        "arm_group": [
            {
                "arm_group_label": "AL-53817", 
                "arm_group_type": "Experimental", 
                "description": "AL-53817 Ophthalmic Solution, 1 drop per eye twice a day for 6 to 8 days and 1 drop per eye one time on the last day of dosing (Day 7, 8 or 9)"
            }, 
            {
                "arm_group_label": "AL-78843", 
                "arm_group_type": "Experimental", 
                "description": "AL-78843 Ophthalmic Solution, 1 drop per eye twice a day for 6 to 8 days and 1 drop per eye one time on the last day of dosing (Day 7, 8 or 9)"
            }, 
            {
                "arm_group_label": "Maxidex", 
                "arm_group_type": "Active Comparator", 
                "description": "0.1% Dexamethasone Ophthalmic Suspension, 1 drop per eye twice a day for 6 to 8 days and 1 drop per eye one time on the last day of dosing (Day 7, 8 or 9)"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "AL-53817 Vehicle Ophthalmic Solution, 1 drop per eye twice a day for 6 to 8 days and 1 drop per eye one time on the last day of dosing (Day 7, 8 or 9)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate two investigational ophthalmic solutions for\n      reduction in ocular redness in subjects with allergic conjunctivitis. Eligible subjects will\n      attend 8 study visits, 5 of which include a 3-hour period of ragweed exposure in an\n      Environmental Exposure Chamber. At the sixth visit, subjects will receive study product and\n      begin dosing for up to 9 days.  The final visit will be the final day of dosing.\n      Participation in this study will last up to 68 days."
        }, 
        "brief_title": "Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sign Informed Consent\n\n          -  Use of condom by sexually active males for the entire duration of the study;\n\n          -  Best corrected visual acuity of 55 or greater in each eye as measured by ETDRS\n             (letters read method).\n\n          -  Able and willing to comply with study protocol and follow protocol instructions.\n\n          -  Able to avoid any of the topical ocular or systemic excluded medications during the\n             entire study period.\n\n          -  At least 1 year subject-reported or physician-diagnosed history (prior to Screen\n             Visit) of allergic conjunctivitis during the ragweed season.\n\n          -  Positive skin prick test for short ragweed allergen within 12 months prior to Screen\n             Visit.\n\n          -  Significant staff-assessed ocular redness in at least one region in each eye within\n             the 3 hour period of allergen exposure in the EEC (Screen Visits).\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential, defined as all women physiologically capable of\n             becoming pregnant, unless they are using highly effective methods of contraception\n             during dosing and for at least 1 week following the last dose of investigational\n             product.\n\n          -  Presence of any ocular infection, history of ocular Herpes (simplex or zoster) or\n             adenoviral infection in either eye.\n\n          -  History of any ocular infection, physician or subject diagnosed, within 30 days prior\n             to Screen Visit.\n\n          -  Presence of glaucoma, past history of, or diagnosis of glaucoma or ocular\n             hypertension.\n\n          -  Presence of blepharitis, active rosacea affecting the ocular adnexa, meibomian gland\n             dysfunction, follicular conjunctivitis, intraocular inflammation, or preauricular\n             lymphadenopathy or any other ophthalmic abnormality that may affect the study\n             outcomes.\n\n          -  Corneal conditions affecting the corneal structure.\n\n          -  Unwilling to discontinue contact lens wear during the study period.\n\n          -  Any ocular surgery including ocular laser procedures within 1 year prior to Screen\n             Visit.\n\n          -  Current or recent (<6 months prior to Screen Visit) history of severe, unstable, or\n             uncontrolled autoimmune, neurological, cardiovascular, hematological, hepatic, renal,\n             psychological, respiratory, gastrointestinal and/or immunological disease or evidence\n             of other diseases based upon a review of medical history and/or physical examination\n             that, in the opinion of the Investigator, would preclude safe subject participation\n             in the study.\n\n          -  Receiving treatment for anxiety and/or depression at the Screen Visit; any history of\n             suicide attempt.\n\n          -  Participation in any investigational study within 30 days of Screen Visit or\n             concomitantly with this study.\n\n          -  Known contraindications or hypersensitivities to any of the study medications or\n             their components\n\n          -  Confirmed (by physician or optometrist) diagnosis of dry eye.\n\n          -  History of sensitivity or adverse reaction to steroids.\n\n          -  Known allergic reaction that is unresponsive to corticosteroids or non-steroidal\n             anti-inflammatory drugs (NSAIDS).\n\n          -  Physician diagnosed asthma (except inactive childhood asthma and exercise-induced\n             asthma).\n\n          -  Evidence of active inflammation in the eye as determined by the dilated fundus\n             examination conducted at Screen C Visit.\n\n          -  Any corneal swelling or haze as determined by the slitlamp examination conducted at\n             Screen C Visit.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079649", 
            "org_study_id": "C-12-069"
        }, 
        "intervention": [
            {
                "arm_group_label": "AL-53817", 
                "intervention_name": "AL-53817 Ophthalmic Solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AL-78843", 
                "intervention_name": "AL-78843 Ophthalmic Solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Maxidex", 
                "intervention_name": "0.1% Dexamethasone Ophthalmic Suspension", 
                "intervention_type": "Drug", 
                "other_name": "Maxidex\u00ae"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Inactive ingredients used as placebo comparator", 
                "intervention_name": "AL-53817 Vehicle Ophthalmic Solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Allergic conjunctivitis", 
            "Red eyes", 
            "Eyelid swelling", 
            "Ragweed", 
            "Allergies", 
            "Itchy eyes", 
            "Ocular redness", 
            "Chemosis", 
            "Tearing", 
            "Watery eyes"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Kay Fisk, RN, BSN", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Change from Baseline in Ocular Redness, Area Under the Curve from Time Zero to Hour 10 [AUC (0-10)] at Day 7", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079649"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Mean Change from Baseline in Ocular Itching, Area Under the Curve from Time Zero to Hour 10 [AUC (0-10)] at Day 7", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 7"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}